The Study of Increased Immunogenicity of UCMSC Stimulated by TLR7 Agonist CL264

YANG Hai-qing, ZHANG Sheng, KUANG Xiao-chuan. et al

Abstract

To study the change of immune status of umbilical cord mesenchymal stem cells (UCMSC) stimulated by toll like receptor 7 (TLR7) agonist CL264. Methods TLR7 specific ligand CL264 was used to stimulate the UCMSC. Flow cytometry was conducted to assay the expression of co-stimulators 〔human leukocyte antigen（HLA）-E, CD80 and CD86〕and surface markers of stem cells (CD29, CD59 and CD90). Quantitative PCR was applied to measure the expression variation of immune-related molecules and stem cell markers. Cell differentiation experiment was used to study the change of differentiation ability of UCMSC upon CL264 stimulation. Peripheral blood mononuclear cells (PBMC) were isolated from healthy human and then co-cultured with UCMSC in the presence of CL264. Cytotoxicity assay was used to measure the attack of PBMC to UCMSC. Results Expression of co-stimulatory molecules CD86 and HLA-E were enhanced in UCMSC upon CL264 stimulation. Real-time PCR indicated that many pro-inflammatory molecules 〔interleukin (\IL) -1β, (\IL)-6, (\IL)-8, (\IL)-10, interferon (\IFN) -β, \IFN-γ, nuclear factor-κB (\NF-κB), transforming growth factor-β （\TGF-β) 〕 were induced in the presence of CL264 while the expression of stem cells markers were inhibited 〔Kruppel-like factor-4 (\Klf4), Nestin, SRY-related high-mobility-group-box protein-2 (\Sox2), \Lin28〕. Activation of TLR7 also increased the immune attack of PBMC on UCMSC. Our study also indicated that the treatment of CL264 did not influence the differentiation ability of UCMSC. Conclusion TLR7 agonist CL264 could increase the immunogenicity of UCMSC.

 

Keywords: Umbilical cord mesenchymal stem cells, Toll like receptor 7CL264, Immunogenicity 

 

Full Text:

PDF


References


Phinney DG, Prockop DJ. Concise review; mesenchymal stem/ multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells, 2007; 25 (11):2896-2902.

Bordignon C, Carlo-Stella C, Colombo MP. et al. Cell therapy; achievements and perspectives. Haematologica, 1999 ; 84(12);1110-1149.

Vojtassak J, Danisovic L. Kubes M, et al. Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett, 2006; 27 Suppl 2; 134- 137.

Guiducci S, Porta F, Saccardi R. et al. Autologus mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis; a case report. Ann Intern Med, 2010;153(10):650-654.

Allison M. Genzyme backs Osiris, despite prochymal flop. Nat Biotechnol. 2009; 27(11);966-967.

Nauta AJ, Westerhuis G, Kruisselbrink AB. et al. Donor- derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood.2006; 108(6) :2114-2120.

Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions; evidence that activated NK cells are capable of killing MSCs, whereas

MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 2006;107(4):1484-1490.

Huang XP. Sun Z. Miyagi Y. et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation.2010; 122(23) :2419-2429.

Li Y. Lin F. Mesenchymal stem cells are injured by complement after their contact with serum. Blood. 2012; 120 (17):3436-3443.

Blasius AL. Beutler B. Intracellular toll-like receptors. Immunity,2010;32(3) :305-315.

DelaRosa O. Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors; implications on therapeutic potential. Mediators Inflamm. 2010; 10 ( 2 ); 865- 601.

Smits EL. Cools N. Lion E. et al. The toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother.2010;59( 1) ;35-46.

Alaina BS. Chen BY. Marc LN. et al. Validation of the 2- calculation as alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diag Mol Path. 2006; 15 ( 1 ) : 56-61.

Si YLi Zhao YL» Hao HJ, et al. Biological characteristics» clinical applications and their outstanding concerns. Age Res Rev,2011;19(1);93-103.

Tolar J, LeBlanck K, Keating A, et al. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells,2011 ;28(8): 1446-1455.

Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells,2006 ;24(10): 74-85.

Nauta A, Kruisselbrink AB, Lurvink E, et al. Mesenchymal stem cells inhibit generation and function of both CD34+- derived and monocyte-derived dendritic cells. J Immunol,2006; 177(4):2080-2087.

Bassi E, Aita CA, Camara NO. Immune regulatory properties of multipotent mesenchymal stromal cells: where do we stand? World J Stem Cells,2011 ;3( 1): 1-8.

Corcione A, Bens'enuto F, Ferretti E. et al. Human mesenchymal stem cells modulate В-cell functions. Blood, 2006;107(1):367-372.

Schon MP. Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene,2008;27(2); 190-199.


Refbacks

  • There are currently no refbacks.